Celling Technologies Announces Initial Success With Res-Q System in Adult Stem Cell Therapy Procedures
RANCHO CORDOVA, Calif., Oct. 13 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL), a leading supplier of innovative products for processing and storing adult stem cells, said today its Res-Q™ 60 BMC (“Res-Q”) System has demonstrated positive outcomes in its initial applications, according to its orthopedic distribution partner Celling Technologies, a subsidiary of SpineSmith, LLC.
In a press release issued by Celling Technologies yesterday, Dr. Mustasim Rumi of Round Rock Orthopedics said, “The Res-Q System was able to yield a high concentration of mononuclear cells, which I believe is one of the key ingredients to bone growth. This technology and Celling’s service team provided me with the confidence that the cells being processed and the sterility of the procurement is the best in the industry. The market of regenerative therapies will change medicine and I believe that such cutting-edge companies give me the best opportunity to deliver the highest care to my patients,” he stated.
“We are pleased with this early experience with the device as we believe the Res-Q System will help us access the growing regenerative medicine market as it has considerable advantages over competing products and has the potential to help surgeons realize the true value of autologous cellular therapy,” said J. Melville Engle, Chief Executive Officer of ThermoGenesis.
“We believe that point-of-care systems provide an immediate and efficient method for delivering adult stem cell therapy to the patients. Our research has confirmed that the Res-Q System has the features and benefits to deliver consistently high yields of mononuclear cells providing the clinician the best opportunity for successful patient outcomes. Over the next several years, we will be working closely with ThermoGenesis and our clinical partners to research and develop continued advancements in the emerging field of regenerative medicine,” said Dr. Jim Poser, Executive Vice President of Regenerative Medicine of Celling Technologies.
Celling, which serves as a distributor for ThermoGenesis’ MXP™ MarrowXpress™ (“MXP”) System - a laboratory device also used to collect stem cells from bone marrow—also announced it is establishing the Institutes of Regenerative Medicine to further research and develop therapies for adult stems cells. As part of this initiative, ThermoGenesis and Celling Technologies will share funding of clinical studies to demonstrate the clinical effectiveness of both the MXP and Res-Q Systems with Celling’s orthopedic applications.
About ThermoGenesis Corp.
ThermoGenesis Corp. (www.thermogenesis.com) is a leader in developing and manufacturing automated blood processing systems and disposable products that enable the manufacture, preservation and delivery of cell and tissue therapy products. These products include:
- The BioArchive® System, an automated cryogenic device, is used by cord blood stem cell banks in more than 25 countries for cryopreserving and archiving cord blood stem cell units for transplant.
- AXP® AutoXpress™ Platform (AXP), a proprietary family of automated devices that includes the AXP and the MXP™ MarrowXpress and companion sterile blood processing disposables for harvesting stem cells in closed systems. The AXP device is used for the processing of cord blood. GE Healthcare is the exclusive global distribution partner for the AXP cord blood product except for Central and South America, China (except Hong Kong), Russia/CIS and Japan, where ThermoGenesis markets through independent distributors. The MXP is used for isolating stem cells from bone marrow.
- The Res-Q™ 60 BMC (Res-Q), a point of care system that is designed for bone marrow stem cell processing. This product was launched in July 2009.
- The CryoSeal® FS System, an automated device and companion sterile blood processing disposable, is used to prepare fibrin sealants from plasma in about an hour. The CryoSeal FS System is approved in the U.S. for liver resection surgeries. The CryoSeal FS System has received the CE-Mark which allows sales of the product throughout the European community. Asahi Medical is the exclusive distributor for the CryoSeal System in Japan and the Company markets through independent distributors in Europe and South America.
This press release contains forward-looking statements, and such statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors, including timing of FDA approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal years 2010, and introduction of competitive products and other factors beyond our control, could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2010. A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.
SOURCE ThermoGenesis Corp.